Teerlink, John R.
University of Copenhagen · Steno Diabetes Center Copenhagen
13 papers on CoChatORCID 0000-0001-9527-0852
Most cited papers
- Verified · note
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association
Bozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · European Journal of Heart Failure
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 1,665
- Verified
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 951
- Verified
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation
Statistical Methods in Clinical TrialsPharmacovigilance and Adverse Drug Reactions
Cited by 750
- Verified
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Packer, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2015) · Circulation
Heart Failure Treatment and ManagementHeart rate and cardiovascular health
Cited by 673
- Verified
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine
Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies
Cited by 656
- Verified
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 435
- Verified
. Effects of serelaxin in patients with acute heart failure
Metra, M., Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., Pang, P. S., Ponikowski, P., Voors, A. A., et al. (2019) · New England Journal of Medicine
Heart Failure Treatment and ManagementPregnancy-related medical research
Cited by 282
- Verified
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
Teerlink, J. R., Clarke, C. P., Saikali, K. G., Lee, J. H., Chen, M. M., Escandon, R. D., Elliott, L., Bee, R., Habibzadeh, M. R., Goldman, J. H., et al. (2011) · The Lancet
Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies
Cited by 262
- Verified
Investigating pain in heart failure patients: the Pain Assessment, Incidence, and Nature in Heart Failure (PAIN-HF) study
Goodlin, S. J., Wingate, S., Albert, N. M., Pressler, S. J., Houser, J., Kwon, J., Chiong, J., Storey, C. P., Quill, T., & Teerlink, J. R. (2012) · Journal of Cardiac Failure
Pain Management and Opioid UseHeart Failure Treatment and Management
Cited by 115
- Verified
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis
Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine
Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension
Cited by 109
- Verified
Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality
Davison, B. A., Metra, M., Senger, S., Edwards, C., Milo, O., Bloomfield, D. M., Cleland, J. G., Dittrich, H. C., Givertz, M. M., O’Connor, C. M., et al. (2016) · European Journal of Heart Failure
Heart Failure Treatment and ManagementAcute Myocardial Infarction Research
Cited by 67
- Verified
Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis
Teerlink, J. R., Davison, B. A., Cotter, G., Maggioni, A. P., Sato, N., Chioncel, O., Ertl, G., Felker, G. M., Filippatos, G., Greenberg, B. H., et al. (2020) · European Journal of Heart Failure
Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling
Cited by 41
- Verified
Blood pressure drops during hospitalization for acute heart failure treated with serelaxin: a patient-level analysis of 4 randomized controlled trials
Grand, J., Miger, K., Sajadieh, A., Køber, L., Torp-Pedersen, C., Ertl, G., López-Sendón, J., Pietro Maggioni, A., Teerlink, J. R., Sato, N., et al. (2022) · Circulation: Heart Failure
Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling
Cited by 6
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free